Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC (US/EU)
Approximately 20% of nonsquamous NSCLC in Western patients is driven by mutations in EGFR, and as such is treated predominantly with agents targeting those alterations. The market is currently dominated by EGFR TKIs, including third-generation EGFR TKI Tagrisso (AstraZeneca), but unmet need remains for drugs offering improved survival and reduced toxicity. 2024 saw the entry into the market of new combination regimens in the first-line metastatic setting: Tagrisso plus chemotherapy; and Rybrevant plus Lazcluze (Johnson & Johnson; Yuhan). These combinations will compete with Tagrisso monotherapy, and the interplay of efficacy and tolerability attributes will be key market-share deciders.
QUESTIONS ANSWERED
- Which attributes most influence prescribers’ decisions for EGFR mutation-positive metastatic nonsquamous NSCLC?
- How do key current therapies, such as EGFR TKIs, perform on key treatment drivers and goals for this patient population?
- What are the prevailing areas of unmet need and hidden opportunities in the treatment of this patient population?
- What trade-offs across different clinical attributes and price are acceptable to surveyed medical oncologists for a hypothetical new first-line treatment for EGFR mutation-positive metastatic nonsquamous NSCLC?
PRODUCT DESCRIPTION
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Markets covered: United States, France, Germany, United Kingdom.
Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in March 2025.
Key companies: AstraZeneca, Boehringer Ingelheim, Cheplapharm, Pfizer, Johnson & Johnson, Roche / Genentech.
Key drugs: Tarceva, Gilotrif / Giotrif, Tagrisso, Rybrevant, Lazcluze.
